LungArchives
Comparison of segmentectomy and lobectomy for non-small cell lung cancer with visceral pleural invasion
Lung 4 min.
Surgical resection is currently the mainstay of curative treatment for early-stage non-small cell lung cancer (NSCLC). Visceral pleural invasion (VPI) has a significant impact on staging and prognosis and is an important factor in determining surgical strategy [1, 2]. Previous studies demonstrated that...
Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer
Lung 3 min.
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small-cell lung cancer (NSCLC) [1, 2]. Among them, atezolizumab demonstrated superior efficacy and safety in the Phase III OAK trial, showing a significant improvement in overall survival (OS) compared with...
A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer
Lung 1 min.
Although immune checkpoint inhibitors (ICIs) form the cornerstone of first-line treatment for non-small cell lung cancer (NSCLC), the challenge remains to improve patients' long-term outcomes. Eftilagimod alfa (efti) activates antigen-presenting cells, triggering T cell activation and a sustained immune...
Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US
Lung 1 min.
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors (PD-[L]1) are standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). This study examined real-world treatment patterns and attrition by lines of therapy (LOTs) among patients with non-driver mutation mNSCLC. ...
